References for Chapter V
Arnesen T, Nord E. The value of DALY life: problems with ethics and validity of disability adjusted life years. BMJ. 2000;320(7246):1398. Pubmed | PMC free article.
Braithwaite RS, Meltzer DO, King JT Jr, et al. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care. 2008;46(4):349-56. PubMed
Briggs A, Clark T, Wolstenholme J, Clarke P. Missing… presumed at random: cost-analysis of incomplete data. Health Econ. 2003;12(5):377-92. PubMed
Byford S, Palmer S. Common errors and controversies in pharmacoeconomic analyses. Pharmacoeconomics. 1998;13(6):659-66. PubMed
Chapman RH, Berger M, Weinstein MC, Weeks JC, Goldie S, Neumann PJ. When does quality-adjusting life-years matter in cost-effectiveness analysis? Health Econ. 2004;13(5):429-36. PubMed
Disease Control Priorities Project, Using Cost-Effectiveness Analysis for Setting Health Priorities. March 2008. Accessed Oct 1, 2013 at: http://www.dcp2.org/file/150/DCPP-CostEffectiveness.pdf.
Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. Third Edition. Oxford: Oxford University Press; 2005.
Elixhauser A, Halpern M, Schmier J, Luce BR. Health care CBA and CEA from 1991 to 1996: an updated bibliography. Med Care. 1998;36(suppl. 5):MS1-9,MS18-147. PubMed
Eccles M, Mason J. How to develop cost-conscious guidelines. Health Technol Assess. 2001;5(16):1-69. PubMed
Garau M, Shah KK, Mason AR, Wang Q, Towse A, Drummond MF. Using QALYs in cancer: a review of the methodological limitations. Pharmacoeconomics. 2011;29(8):673-85.PubMed
Gerard K, Mooney G. QALY league tables: handle with care. Health Economics. 1993;2(1):59-64. PubMed
Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
Graves N, Walker D, Raine R, et al. Cost data for individual patients included in clinical studies: no amount of statistical analysis can compensate for inadequate costing methods. Health Economics. 2002;11(8):735-9. PubMed
Greenberg D, Neumann PJ. Does adjusting for health-related quality of life matter in economic evaluations of cancer-related interventions? Expert Rev Pharmacoecon Outcomes Res. 2011;11(1):113-9.PubMed
Hjelmgren J, Berggren F, Andersson F. Health economic guidelines--similarities, differences and some implications. Value Health. 2001;4(3):225-50.PubMed
Hogness JR,Van Antwerp M. The Artificial Heart: Prototypes, Policies, and Patients. Washington, DC: National Academy Press; 1991. Used with permission from the National Academy of Sciences, courtesy of the National Academies Press, Washington, DC. Pubmed | Bookshelf free book
Husereau D, Drummond M, Petrou S, Carswell C, et al. ; CHEERS Task Force. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Int J Technol Assess Health Care. 2013;29(2):117-22. PubMed
IQWiG (Institute for Quality and Efficiency in Health Care). General Methods for the Assessment of the Relation of Benefits to Costs. Version 1.0 – 19/11/2009. Accesed Aug. 1, 2013 at: https://www.iqwig.de/download/General_Methods_for_the_Assessment_of_the_Relation_of_Benefits_to_Costs.pdf.
Mauskopf JA, Sullivan SD, Annemans L, Caro J, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis. Value Health. 2007;10(5):336-47. PubMed
Maynard A. Developing the health care market. Econ J. 1991;101(408):1277-86.
McGhan WF, Al M, Doshi JA, Kamae I, Marx SE, Rindress D. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report. Value Health. 2009;12(8):1086-99. PubMed
Neuhauser D, Lewicki AM. What do we gain from the sixth stool guaiac? N Engl J Med. 1975;293(5):226-8. PubMed
Neumann PJ, Weinstein MC. Legislating against use of cost-effectiveness information. N Engl J Med 2010;363(16):1495-7. http://www.nejm.org/doi/full/10.1056/NEJMp1007168. PubMed
Nixon J, Stoykova B, Glanville J, Christie J, Drummond M, Kleijnen J. The U.K. NHS Economic Evaluation Database. Economic issues in evaluations of health technology. Int J Technol Assess Health Care. 2000; 16(3): 731-42. PubMed
Nord E. The QALY − a measure of social value rather than individual utility? Health Econ. 1994;3(2):89-93. PubMed
Orlewska E, Gulácsi L. Budget-impact analyses: a critical review of published studies. Pharmacoeconomics. 2009;27(10):807-27. PubMed
Poe NR, Griffiths RI. Clinical-economic Trials. In Tools for Evaluating Health Technologies: Five Background Papers. US Congress, Office of Technology Assessment, BP-H-142, 125-49. Washington, DC: US Government Printing Office; 1995. GPO free book.
Rettig RA, Levinsky NG, eds. Kidney Failure and the Federal Government. Washington, DC: National Academy Press; 1991. Publisher free book.
Trueman P, Drummond M, Hutton J. Developing guidance for budget impact analysis. Pharmacoeconomics. 2001;19(6):609-21. PubMed
Ubel PA, Nord E, Gold M, et al. Improving value measurement in cost-effectiveness analysis. Med Care. 2000;38(9):892-901. PubMed
Weinstein MC. How much are Americans willing to pay for a quality-adjusted life year? Med Care. 2008;46(4):343-5. PubMed
Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med. 1977;296(13):716-21. PubMed
Willke RJ, Glick HA, Polsky D, Schulman K. Estimating country-specific cost-effectiveness from multinational clinical trials. Health Econ. 1998;7(6):481-93. PubMed
Wonderling D, Sawyer L, Fenu E, Lovibond K, Laramée P. National Clinical Guideline Centre cost-effectiveness assessment for the National Institute for Health and Clinical Excellence. Ann Intern Med. 2011;154(11):758-65. PubMed